These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling. Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160 [TBL] [Abstract][Full Text] [Related]
5. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva. Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737 [TBL] [Abstract][Full Text] [Related]
6. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP). Wang H; Shore EM; Pignolo RJ; Kaplan FS Bone; 2018 Apr; 109():218-224. PubMed ID: 29170109 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification. Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634 [TBL] [Abstract][Full Text] [Related]
8. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933 [TBL] [Abstract][Full Text] [Related]
9. iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva. Gao P; Inada Y; Hotta A; Sakurai H; Ikeya M Stem Cell Res Ther; 2024 Mar; 15(1):83. PubMed ID: 38500216 [TBL] [Abstract][Full Text] [Related]
10. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2. Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088 [TBL] [Abstract][Full Text] [Related]
11. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva. Pang J; Zuo Y; Chen Y; Song L; Zhu Q; Yu J; Shan C; Cai Z; Hao J; Kaplan FS; Shore EM; Zhang K Bone; 2016 Nov; 92():29-36. PubMed ID: 27492611 [TBL] [Abstract][Full Text] [Related]
12. Dysregulated BMP signaling through ACVR1 impairs digit joint development in fibrodysplasia ossificans progressiva (FOP). Towler OW; Peck SH; Kaplan FS; Shore EM Dev Biol; 2021 Feb; 470():136-146. PubMed ID: 33217406 [TBL] [Abstract][Full Text] [Related]
13. How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva. Srinivasan D; Arostegui M; Goebel EJ; Hart KN; Aykul S; Lees-Shepard JB; Idone V; Hatsell SJ; Economides AN Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254701 [TBL] [Abstract][Full Text] [Related]